evaluating the combination of nivolumab and lenalidomide in relapsed hl and lbcl
Published 1 year ago • 80 plays • Length 2:29Download video MP4
Download video MP3
Similar videos
-
1:15
swog s1826: promising results with the combination of nivolumab-avd in hodgkin lymphoma
-
3:04
nivahl: nivolumab and avd in early-stage unfavorable hl
-
1:59
updates on the use of nivolumab in hodgkin lymphoma & how this agent may impact treatment
-
7:51
phase i study shows nivolumab is safe and tolerable for relapsed or refractory hodgkin lymphoma
-
1:21
checkmate 205: the use of nivolumab to treat relapsed hodgkin lymphoma
-
1:01:07
understanding diagnostic & biomarker testing | lrf webinars
-
46:33
understanding biomarker testing
-
4:38
advocating for hodgkin lymphoma care: jenny's immunotherapy story
-
1:09
novel immunotherapy combinations in hodgkin lymphoma
-
1:24
novel agents for the treatment of hodgkin lymphoma: brentuximab vedotin and nivolumab
-
1:28
checkmate 205: factors associated with pfs in patients with r/r hl treated with nivolumab
-
0:35
nivolumab and pembrolizumab and the current treatment landscape for hodgkin lymphoma
-
2:50
nivolumab and allogeneic transplantation in r/r classical hodgkin lymphoma
-
1:41
swog s1826: nivolumab avd vs brentuximab vedotin avd for advanced stage hodgkin lymphoma
-
1:25
results of checkmate 039 trial of nivolumab in combination with ipilimumab for hodgkin lymphoma
-
2:15
updates from the phase ii aern trial: nivolumab and radiotherapy for the treatment of r/r hl
-
1:44
updates from the phase ii animate trial of nivolumab in r/r chl
-
1:10
checkmate study and the role of nivolumab in hodgkin lymphoma
-
1:29
updates on the diagnosis, risk stratification and management of hl
-
2:11
novel approaches in hl
-
2:09
response biomarkers in hl
-
2:41
an overview of the latest advances in hematology